Epileptogenic mechanisms in focal cortical dysplasia (FCD) remain elusive, as no animal models faithfully recapitulate FCD seizures, which have distinct electrographic features and a wide range of semiologies. Given that DEPDC5 plays significant roles in focal epilepsies with FCD, we used in utero electroporation with clustered regularly interspaced short palindromic repeats gene deletion to create focal somatic Depdc5 deletion in the rat embryonic brain. Animals developed spontaneous seizures with focal pathological and electroclinical features highly clinically relevant to FCD IIA, paving the way toward understanding its pathogenesis and developing mechanistic-based therapies. ANN NEUROL 2018;84:140-146 F ocal cortical dysplasia (FCD) is a common cause of refractory focal epilepsies (FEs). As the most common underlying pathology in children with refractory FEs, it accounted for 26.8% of those cases in a series of approximately 2,600 specimens of brain tissue obtained during epilepsy surgery.
Epileptogenic mechanisms in focal cortical dysplasia (FCD) remain elusive, as no animal models faithfully recapitulate FCD seizures, which have distinct electrographic features and a wide range of semiologies. Given that DEPDC5 plays significant roles in focal epilepsies with FCD, we used in utero electroporation with clustered regularly interspaced short palindromic repeats gene deletion to create focal somatic Depdc5 deletion in the rat embryonic brain. Animals developed spontaneous seizures with focal pathological and electroclinical features highly clinically relevant to FCD IIA, paving the way toward understanding its pathogenesis and developing mechanistic-based therapies. ANN NEUROL 2018; 84:140-146 F ocal cortical dysplasia (FCD) is a common cause of refractory focal epilepsies (FEs). As the most common underlying pathology in children with refractory FEs, it accounted for 26.8% of those cases in a series of approximately 2,600 specimens of brain tissue obtained during epilepsy surgery. 1 FCD has been classified into several subtypes and entities on the basis of histopathology. In particular, FCD II is an isolated lesion characterized by disrupted cytoarchitecture including dysmorphic neurons without (FCD IIA) or with balloon cells (FCD IIB).
1,2
Although FCD II is firmly linked to aberrant MTOR signaling pathways, 3 a major challenge in understanding its epileptogenesis and intractability is to develop animal models that recapitulate its genetics, pathology, and electroclinical expression. For example, transgenic rodent, antimitotic agent, and irradiation models lack a focal lesion. Freeze lesions produce circumscribed lesions but fail to capture its genetics and pathologies. Recently, focal pathology was replicated in mouse models using in utero electroporation (IUE) to focally knockdown the mTOR inhibitor Tsc1/2 or overexpress mutant mTOR activators. 4 However, a fundamental impediment to clinical translation is that none of these models had focal electrographic signatures of human FCD seizures such as paroxysmal fast activity (PFA) 5 or fingerprints for the epileptogenic zone including low-voltage fast activity (LVFA). 6 Whereas nearly all patients develop seizures with various semiologies, these FCD animals only displayed generalized tonic-clonic seizures (GTCs), and a significant number of them did not develop spontaneous seizures. 7 The focal lesion seen in FCD II has led to the hypothesis that somatic mosaic mutations are the underlying genetic mechanism. Recent work has identified somatic activating mutations in MTOR itself, genes encoding positive regulators of MTOR, and new genes as negative regulators of MTOR via germline loss-of-function (LoF) mutation coupled to demonstrated or inferred somatic loss of the second allele. 8 Germline or somatic DEPDC5 mutations are increasingly recognized as the common cause of familial or sporadic FEs including monogenic entities such as familial focal epilepsy with variable foci, autosomal dominant nocturnal frontal lobe epilepsy, and familial temporal lobe epilepsy. 9 In addition to its role in magnetic resonance imaging (MRI)-negative FEs, DEPDC5 has also been associated with epileptogenic structural brain malformations, from FCD to large cortical malformations, such as hemimegalencephaly. 8 DEPDC5 is part of a complex named GAP activity toward RAGs complex 1 (GATOR1), together with the proteins NPRL2 and NPRL3. As a key member of the amino acid sensing machinery, GATOR1 functions independently of TSC1/TSC2 signaling and directly inhibits mTORC1 recruitment to lysosomal membranes. 10 However, no DEPDC5-related FEs animal model exists, and all Depdc5 transgenic animals reported to date failed to develop spontaneous seizures. All homozygous knockout animals died embryonically, whereas heterozygous knockouts showed either no or subtle pathologies. 11 Although a neuron-specific Depdc5 conditional knockout mouse survived to adulthood with severe neurological phenotypes, spontaneous focal electroclinical seizures were not recorded. 11 Given its significant role in FEs and unique function in MTOR pathway, we performed IUE with clustered regularly interspaced short palindromic repeats (CRISPR) gene editing (CRISPR-IUE) on rat brains at embryonic day (E) 13 to E14 to introduce a focal region with somatic Depdc5 deletion and generated animals with pathological and electroclinical expression highly similar to human FCD IIA. The final concentrations used for transfections were 0.5 μg/μl for eGFP and 1.5 μg/μl for Depdc5 CRISPR gRNA/Cas9. To track the entire lineage of transfected neural progenitors, PBCAG-eGFP (0.5 μg/μl) and pCAG-PBase (1 μg/μl) were coelectroporated with Depdc5 CRISPR gRNA/Cas9. pCAG-eCas9-T2A-GFP-U6-gRNA plasmid (a gift from Jizhong Zou; Addgene plasmid # 79145) was used at 1.5 μg/ μl. All animal studies were approved by the institutional animal care and use committee of the University of Michigan.
Materials and Methods

Plasmids, IUE, and Animals
Next Generation Sequencing
To estimate the rate of somatic Depdc5 LoF mosaicism in the cortex, Depdc5 CRIPSR-IUE-transfected cortex was resected under the fluorescent dissection microscope. 
Long-Term Electroencephalographic Recording and Analysis
To determine if rats that underwent Depdc5 CRISPR-IUE exhibit electroclinical seizures and interictal epileptiform discharges (IEDs), we monitored animals with continuous videoelectroencephalography (EEG). Rats were implanted with 4 epidural screw electrodes at P60. Procedures for affixing electrodes were performed as previously described. 14 Four burr holes were made, and electrodes were positioned and fastened (left and right parietal, 1 cerebellar, and 1 reference posteriorly over the sinus cavity) using mounting screws (E363/20; PlasticsOne, Roanoke, VA). The sockets were fitted into a 6-pin electrode pedestal, and the entire apparatus was secured with dental cement (Stoelting, Wood Dale, IL). One week after surgery, animals were monitored continuously for 3 to 14 days by video-EEG recording (Natus, Middleton, WI). Recordings were sampled at 4,056Hz and were analyzed offline with concurrent video. Seizures and epileptiform activity were assessed manually in their entirety by fellowship-trained and board-certified epileptologists blind to experiments. IEDs are described as transients distinguishable from background activity with a characteristic morphology, typically but neither exclusively nor invariably found in interictal EEGs of people with epilepsy. Epileptiform patterns have to fulfill at least 4 of the following 6 criteria: (1) di-or triphasic waves with sharp wave or spike morphology (<200-millisecond duration); (2) different wave duration than the ongoing background activity; (3) asymmetry of the waveform, a sharply rising ascending phase and a more slowly descending phase, or vice versa; (4) transient is followed by an associated after-going slow wave; (5) background activity surrounding epileptiform discharges is disrupted by the presence of the epileptiform discharges; and (6) distribution of the negative and positive potentials on the scalp suggests a source of the signal in the brain. 15 Seizures are defined as EEG phenomenon consisting of repetitive epileptiform EEG discharges at >2 cycles/s and/or characteristic pattern with quasi-rhythmic spatiotemporal evolution (ie, gradual change in frequency, amplitude, morphology, and location), lasting at least several seconds (usually > 10 seconds). Two other short duration (<10 seconds) EEG seizure patterns are defined as electrodecrement or LVFA seen during clinically apparent epileptic seizures. EEG seizure patterns unaccompanied by behavioral epileptic manifestations are referred to as electrographic or subclinical seizures. 15 For detection of sleep state, EEG voltage data were converted into a time-frequency power graph using a multitaper method at 1-second resolution. Each second was automatically classified into non-rapid eye movement or wakelike states based on bimodality tests of cortical signals as previously described. 16 Please see code in SleepScoreMaster.m file in the GitHub repository at https://github.com/buzsakilab/buzcode.
Immunocytochemistry
Brains were removed and fixed in 4% paraformaldehyde in phosphate-buffered saline after transcardial perfusion, sectioned at 50 to 80 μm on a vibratome (VT1000S; Leica, Wetzlar, Germany), and processed for immunocytochemistry as free-floating sections. 
Brain Slice Preparation, Electrophysiological Recordings, and Data Analysis
Male and female rats (P21-P28) that previously underwent IUE at E13 were used for electrophysiological recordings. Slices were prepared as previously described. 12 Electrophysiological recordings were made in a recording chamber mounted on the stage of an upright microscope (customized Scientifica [Uckfield, UK] optical platform). Slices were continuously perfused (miniplus 3; Gilson, Middleton, WI) with artificial cerebrospinal fluid containing 1 μM tetrodotoxin, 20 μM 6-cyano-7-nitroquinoxaline-2,3-dione, and 20 μM d(−)2-amino-5-phosphonovaleric acid to block action potential firing and ionotropic glutamate currents at a rate of 5 to 6ml/min at 31-32 C (in-line heater TC-324B;
Warner Instruments, Hamden, CT). GFP-expressing cells in cortical layers 2 and 3 were targeted for recordings. Resistance micropipettes (3-5MΩ) were filled with an internal solution containing (in mM) 100 Cs-gluconate, 0.2 ethyleneglycoltetraacetic acid, 5 MgCl 2 , 40 hydroxyethylpiperazine ethane sulfonic acid, 2 Mg-ATP, 0.3 Na-GTP, 1 QX-314, pH 7.2. Data were acquired at 20kHz and filtered at 5kHz. Only cells with stable passive properties were further analyzed. We collected data from a maximum of 3 neurons per animal to avoid bias. Statistical analysis was performed using Prism (GraphPad Software, La Jolla, CA). Average values for each of the variables were calculated per cell and further averaged for each experimental group. Parametric and nonparametric statistical analyses were performed as dictated by data distribution.
Image Acquisition, Soma Size Measurements, and Statistical Analyses
Multichannel imaging was performed using a Leica SP5 confocal microscope. All the images were further processed with Photoshop CS3 software (Adobe Systems, San Jose, CA). The soma size of GFP-positive neurons from P21P30 brains were compared between control and Depdc5 CRISPR IUE animals. Automated measurement was performed in ImageJ. Statistical analysis was performed using Excel (Microsoft, Redmond, WA) and GraphPad. Three or more biological replicates were used for all studies. A confidence interval of 95% (p < 0.05) was required for values to be considered statistically significant. All data are presented as mean ± standard error of the mean unless noted otherwise.
Results
Phosphorylated ribosomal protein S6 (pS6) is commonly used as a marker of mTORC1 activity because mTORC1 activates p70 S6 kinase 1, which phosphorylates S6. 10 To examine mTORC1 hyperactivation, immunostaining for pS6 was performed on brain sections from 3-week-old rats that were coelectroporated with a Depdc5 gRNA/Cas9 construct and a GFP-encoding plasmid (Fig 1) . After Depdc5 CRISPR-IUE, pS6 immunoreactivity and soma size significantly increased in GFP-expressing neurons as compared to control CRISPR transfected brains. Interestingly, cell non-autonomous mTOR hyperactivation was observed in GFP-negative neurons with substantial extension to overlying and adjacent cortex, in line with clinical data indicating that histological and electrographic abnormalities occur beyond MRI-visualized margins. 17 Antibodies to nonphosphorylated neurofilament proteins (SMI32) revealed aberrant cytoplasmic accumulation of neurofilament proteins in the dysplastic cortex of Depdc5 CRISPR-IUE rats, consistent with pathological findings observed in human FCD II. 2 However, nestin-positive cells, a hallmark of balloon cells in human FCD IIB, were not observed. These findings suggest that focal Depdc5 somatic mutations in rat cortex generate human FCD IIA pathologies. Although we did not quantify the efficiency of Depdc5 gRNAs, we and other groups have shown that IUE-CRISPR achieves gene knockout efficiency of >80%. 12, 18 The specificity of Depdc5 deletion was confirmed by finding similar cellular and electrographic phenotypes using gRNAs targeting 2 different Depdc5 exons. Specificity was further supported by pharmacological rescue experiments showing that treatment with the rapamycin analog everolimus normalized soma size.
To estimate the degree of somatic Depdc5 LoF mosaicism, genomic DNA was extracted from the dysplastic cortex resected under fluorescent microscope. Targeted genomic areas flanking gRNA binding sites were PCR amplified and sent for next generation sequencing (>70,000 reads). The rate of Depdc5 LoF mosaicism ranged from 2.64% to 3.22 % (n = 3). Whole cell patch clamp recordings of acute cortical slices showed firing of doublet spikes and decreased input resistance in GFP-labeled cortical neurons with Depdc5 deletion. Critically, 100% (11/11 from > 3 different litters) of rats undergoing Depdc5 IUE-CRISPR developed frequent focal IEDs and spontaneous seizures. IEDs were restricted to the hemisphere with dysplastic tissue, in contrast to generalized discharges with current FCD models (Fig 2) . Importantly, PFA, rhythmic spikes, and periodic lateralized epileptiform discharges (PEDs), hallmarks of human FCD II, 5 were detected in the rats as well as our FCD II patients.
High-frequency oscillations was also lateralized to the lesional side, supporting focal epileptogenicity. IEDs were also highly sleep-dependent. Ictally, electrographic seizure onsets were lateralized to the lesional hemisphere, and the common onset patterns in patients with FEs, including focal LVFA, rhythmic spikes, background suppression, and PEDs, 6 were frequently observed (Fig 3A, C, D) . These electrographic features were similar to those seen with intracranial ictal EEG recordings in FCD II patients and 1 patient with a pathological Depdc5 mutation (see Fig  3B) . Semiologically, the clinical seizure expression in rats, including behavioral arrest, tonic stiffening, and contralateral clonic activity (Supplementary Videos 1-5), more closely recapitulates the variability seen in human FCD than existing models that show limited semiologies or only GTCs. 7 For example, behavioral arrest was commonly observed in these rats, similar to human complex partial seizures. Many seizures presented with subtle clinical/ behavioral changes, such as waking up and subtle trunk tonic posturing. GTCs occasionally occurred late into the seizure but never occurred at the onset.
Discussion
To our knowledge, this is the first animal model that recapitulates genetics, pathology, and most importantly, electroclinical features of human FCD IIA. We did not observe nestin-positive balloon cells that are typically seen in human FCD IIB. 3 Considering the striking difference in neurogenesis between humans and rodents, particularly the absence of outer radial glia cells in rodents, 13 it is probably not a surprise that a rodent model lacks certain cytoarchitectural features. In addition, balloon cells have been shown to be silent electrographically. 19 Genetically, germline DEPDC5 mutations occur more often than all other mutations in FE-related genes combined 9 and directly inhibit MTOR independently of TSC1/TSC2. 10 Although DEPDC5 somatic mutations have been associated with brain malformations from FCD to hemimegalencephaly, 9 how a germline mutation sustains a focal pattern in inherited epilepsies still remains enigmatic. A plausible emerging hypothesis is that DEPDC5 germline LoF mutation together with a second biallelic somatic hit in DEPDC5 itself leads to the development of FCD, known as "2-hit" mechanism, initially described in cancer and tuberous sclerosis. 9 This biallelic inactivation hypothesis is also supported by a recent report of a DEPDC5 somatic nonsense variant in resected brain tissue from an individual with FCD IIA and a familial history of FEs due to a germline mutation in DEPDC5. 9 Pathologically, both cell-autonomous and cell non-autonomous mTOR hyperactivation was observed in our model, in line with the clinical observation that FCD histologic and electrographic abnormality occurs beyond the MRI margin. 17 Clinically, our Depdc5 CRISPR-IUE rats have a distinctly different electroclinical repertoire from current FCD models. The full spectrum of seizure semiologies and characteristic interictal and ictal discharges are unique and highly clinically relevant to human FCD. However, 2 important questions remain to be answered. First, cell non-autonomous mTOR hyperactivation, a surprising finding, likely plays an important role in epileptogenesis and overall clinical manifestations. However, the mechanism is completely unknown. Second, interneurons are firmly tied to ictogenesis and epileptogenesis in FCD. 20 However, they are born in the ventral medial ganglionic eminence and lateral ganglionic eminence, 21 which are not transfected by Depdc5 CRISPR-IUE. A unifying hypothesis would be that cell nonautonomous mTOR hyperactivation impairs interneuron development. Our model should pave the way to study epileptogenesis and ictogenesis at cellular and circuit levels, as well as to develop mechanistic-based therapies.
